ISRCTN75847548 https://doi.org/10.1186/ISRCTN75847548

Phase III study evaluating the efficacy of Drogenil in pancreatic carcinoma

Submission date 19/08/2002	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol [_] Statistical analysis plan [X] Results [_] Individual participant data
Registration date 19/08/2002	**Overall study status** Completed	
Last Edited 30/10/2019	**Condition category** Cancer	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr - -

Contact details
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
NHS_1

Study information

Scientific Title
Phase III study evaluating the efficacy of Drogenil in pancreatic carcinoma

Study objectives
Not provided at time of registration

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Hospital

Study type(s)
Treatment

Participant information sheet
Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied
Carcinoma of the pancreas

Interventions
1. Group A: Flutamide 250 mg three times daily
2. Group B: Placebo

Intervention Type
Drug

Phase
Phase III

Drug/device/biological/vaccine name(s)
Drogenil (flutamide)

Primary outcome measure
Not provided at time of registration

Secondary outcome measures
Not provided at time of registration

Overall study start date
01/01/1995

Completion date
31/01/1997

Eligibility

Key inclusion criteria
Not provided at time of registration

Participant type(s)
Patient

Age group
Not Specified

Sex
Not Specified

Target number of participants
Not provided at time of registration

Key exclusion criteria
Not provided at time of registration

Date of first enrolment
01/01/1995

Date of final enrolment
31/01/1997

Locations

Countries of recruitment
England

United Kingdom

Study participating centre
MRC Clinical Trials Unit
London
United Kingdom
NW1 2DA

Sponsor information

Organisation
Schering-Plough Ltd (UK)

Sponsor details
Schering-Plough House
Shire Park
Welwyn Garden City
United Kingdom
AL7 1TW

Sponsor type
Industry

ROR
https://ror.org/00148fb49

Funder(s)

Funder type
Industry

Funder Name
Schering-Plough Ltd (UK)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	presumed results	27/06/1998	30/10/2019	Yes	No